OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Goel on the Safety Profile of Tinengotinib in Solid Tumors

September 1st 2023

Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

August 31st 2023

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Dr Callahan on Commonly Used Imaging Modalities in Breast Cancer

August 31st 2023

Rena D. Callahan, MD, discusses the range of metastatic imaging techniques available in breast cancer, the benefits of liquid biopsy, and the importance of looking for bone metastases in patients with metastatic breast cancer.

Dr Fonkoua on Addressing Barriers to Cancer Clinical Trial Access

August 31st 2023

Lionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.

Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer

August 31st 2023

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL

August 31st 2023

Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.

Dr Gatti-Mays on Updated Biomarker Data From the NeoPACT Study in TNBC

August 31st 2023

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses updated biomarker data from the phase 2 NeoPACT trial of neoadjuvant chemoimmunotherapy in triple-negative breast cancer.

Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

August 31st 2023

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Dr Goel on the Mechanism of Action of Tinengotinib in Solid Tumors

August 30th 2023

Sanjay Goel, MD, MS, discusses the mechanism of action of tinengotinib and the efficacy of this agent in patients with cholangiocarcinoma.

Dr Williams on the Evolution of Treatment Approaches in Ovarian Cancer

August 30th 2023

Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

August 30th 2023

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.

Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer

August 30th 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Dr Barzi on the Evolution of Treating Gastroesophageal Cancers

August 30th 2023

Afsaneh Barzi, MD, PhD, discusses challenges treating oncologists face when aiming to navigate the treatment landscape of patients with gastroesophageal cancers and highlights the evolution of treatments for patients with these diseases.

Dr Cannon on Improving Responses With Immunotherapy in Ovarian Cancer

August 30th 2023

Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.

Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

August 30th 2023

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Dr Le on the Investigation of Osimertinib and Chemotherapy in Metastatic Lung Cancer

August 29th 2023

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

Dr Fonkoua on Clinical Trial Enrollment Disparities in Liver Cancer

August 29th 2023

Lionel A. Kankeu Fonkoua, MD, discusses prevalent liver cancer clinical trial enrollment disparities.

Dr Kambhampati on the Potential Use of Brexu-Cel in Earlier Treatment Lines in MCL

August 29th 2023

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.

Dr Monga on the Background of Investigating PRT811 in Glioma and Melanoma

August 29th 2023

Varun Monga, MD, discusses the background for investigating the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in a phase 1 study in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

August 29th 2023

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.